Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.240
+0.040 (3.33%)
Mar 9, 2026, 2:20 PM EDT - Market open
Rein Therapeutics Employees
Rein Therapeutics had 11 employees as of December 31, 2024. The number of employees decreased by 4 or -26.67% compared to the previous year.
Employees
11
Change (1Y)
-4
Growth (1Y)
-26.67%
Revenue / Employee
n/a
Profits / Employee
-$5,353,182
Market Cap
32.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Werewolf Therapeutics | 39 |
| Lantern Pharma | 24 |
| Tempest Therapeutics | 21 |
| ABVC BioPharma | 19 |
| Outlook Therapeutics | 17 |
| NeuroSense Therapeutics | 17 |
| FibroBiologics | 15 |
RNTX News
- 4 months ago - Why Is Rein Therapeutics Stock Trading Higher On Monday? - Benzinga
- 5 months ago - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 6 months ago - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 7 months ago - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 7 months ago - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewsWire
- 9 months ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 9 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
- 10 months ago - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PRNewsWire